NCT04083196已完成1 期
A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
National Vaccine and Serum Institute, China1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2019年9月7日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 90
- 试验地点
- 1
- 主要终点
- All active AEs within 0-7 days after each dose
研究概览
简要总结
A total of 90 Chinese women aged 9-45 years old were divided into three age groups: 27-45 years old, 18-26 years old, and 9-17 years old. The experimental group and the placebo group were randomly assigned in a ratio of 2:1. Sixty patients had a placebo group of 30 patients. All subjects enrolled in the upper arm deltoid muscle were injected with 3 doses of test vaccine or placebo according to the 0, 2, and 6 months immunization program.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 9 Years 至 45 Years（Child, Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Chinese women aged 9-45 who can provide legal identification;
- •The legal guardian of the subject and/or subject has the ability to understand the research procedure and sign an informed consent form (a 9-17 year old subject signs an informed notification); 3).The legal guardian of the subject and / or subject has the ability to read, understand, fill in the journal card / contact card, and promise to participate in regular follow-up as required by the study;
- •Female children of childbearing age were not pregnant at the time of enrollment (negative urine pregnancy test), did not have lactation period and had no birth plan within the first 7 months after enrollment; effective contraceptive measures were taken within 2 weeks before enrollment in the study. And agree to continue to take effective contraceptive measures within the first 7 months after the study (effective contraceptives include: oral contraceptives, injection or embedding contraceptives, sustained release topical contraceptives, hormone patches, intrauterine devices) (IUD), sterilization, abstinence, condoms (male), diaphragms, cervical caps, etc.
排除标准
- •Previously vaccinated with commercially available HPV vaccines or planned to vaccinate commercially available HPV vaccines during the study period or have participated in HPV vaccine clinical trials and have received vaccine/placebo vaccination;
- •History of cervical lesions (such as cervical cancer screening abnormalities, history of CIN disease) or history of hysterectomy (vaginal or total abdominal hysterectomy) or history of pelvic radiation therapy; history of external genital diseases (such as vulvar epithelialization) Tumor, vaginal intraepithelial neoplasia and genital warts, etc. or acute genital infections (eg acute vaginitis, acute endometritis, acute salpingitis and oophoritis); or previous history of sexually transmitted diseases (including syphilis) Gonorrhea, genital warts, genital chlamydia infection, genital herpes, soft chancre, sexually transmitted lymphogranuloma, inguinal granuloma, etc.);
- •Have a history of severe allergies to any of the components of the test vaccine, including yeast, L-histidine, sodium chloride, aluminum hydroxide and water for injection, eg anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenia Sexual purpura, local allergic necrosis (Arthus reaction); or any previous history of serious side effects of vaccines or drugs, such as: allergies, urticaria, skin eczema, dyspnea, angioedema, etc.;
- •There is thrombocytopenia or other coagulopathy that can be a contraindication to intramuscular injection;
- •impaired immune function or has been diagnosed as having congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile Rheumatoid arthritis (JRA), inflammatory bowel disease or other autoimmune diseases;
- •no spleen or functional spleen, and no spleen or splenectomy caused by any condition;
- •has been diagnosed as having an infectious disease, such as: tuberculosis, hepatitis B, hepatitis C, etc.;
- •Before the enrollment, the physical examination was hypertension (systolic blood pressure ≥140mmHg and / or diastolic blood pressure ≥90mmHg) (applicable to 18-45 year olds);
- •suffering from severe cardiovascular disease (pulmonary heart disease, pulmonary edema), severe liver and kidney disease, and complications of diabetes;
- •3 days before vaccination, suffering from acute illness or acute exacerbation of chronic disease;
- •have convulsions, epilepsy, encephalopathy, mental illness or family history;
- •Inactivated vaccine or recombinant vaccine within 14 days before vaccination, or vaccinated with any live vaccine within 28 days;
- •Participated in other gynecological related clinical trials within 6 months, participated in other research or unregistered products (drugs or vaccines) within 3 months, or planned to participate in other clinical studies after the clinical study was enrolled;
- •receive any immunoglobulin or blood product within 6 months prior to the first injection, or plan to receive such product by the 7th month of the study;
- •In the past 6 months, there have been immunosuppressive drugs, systemic medication for corticosteroids (≥2mg/kg/day, continuous use ≥14 days), but local medication (such as ointment, eye drops, inhalants) Or nasal spray), the topical medication should not exceed the recommended dose in the instructions or have any systemic exposure signs;
- •The body temperature before inoculation on the day of enrollment> 37.0 ° C (armpit temperature);
- •Before the first dose is vaccinated, the laboratory test indicators specified in the program are abnormal and clinically determined by the clinician;
- •plan to move out of the country before the end of the study or leave the local area for a long time during the scheduled study visit;
- •The investigator believes that the subject has any condition that may interfere with the assessment of the purpose of the study.
结局指标
主要结局
All active AEs within 0-7 days after each dose
时间窗: 7 days
Active AE: Local and systemic adverse reactions occurring within 0-7 days after each dose of vaccination
All SAEs within 6 months after the first dose is vaccinated
时间窗: 6 months
All non-active collection AEs within 0-30 days after each dose
时间窗: 30 days
Adverse events other than active AE include solicitation adverse events reported in addition to the specified solicitation time window
AE of local and systemic reactions within 30 minutes after each dose
时间窗: 30 min
次要结局
- Neutralizing antibody positive rate of anti-HPV6, 11, 16, 18, 31, 33, 45, 52, 58, 59 and 68 antibodies 30 days after full immunization(7 months)
- Geometric mean titer of neutralizing antibodies against HPV types 6, 11, 16, 18, 31, 33, 45, 52, 58, 59 and 68 30 days after full immunization (Geometric Mean Titer, GMT)(7 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A study to compare the pharmacokinetics and pharmacodynamics of the free base form of PRTX007, the hydrochloride salt form of PRTX007 and the hydrochloride salt form of PRTX007 in combination with probenecid in healthy adultsACTRN12623000468628Primmune Therapeutics Australia Pty Ltd18
进行中（未招募）
1 期
A Randomized, Double Blinded, Study of Two Different Dose Combinations of Nivolumab in Combination with Ipilimumab in Subjects with Previously Untreated, Unresectable or Metastatic MelanomaSubjects with Previously Untreated, Unresectable or Metastatic MelanomaMedDRA version: 18.1Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-004920-67-ESBristol-Myers Squibb International Corporation385
进行中（未招募）
1 期
A Randomized, Double Blinded, Study of Two Different Dose Combinations of Nivolumab in Combination with Ipilimumab in Subjects with Previously Untreated, Unresectable or Metastatic MelanomaSubjects with Previously Untreated, Unresectable or Metastatic MelanomaMedDRA version: 20.0Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-004920-67-GBBristol-Myers Squibb International Corporation460
进行中（未招募）
1 期
A Randomized, Double Blinded, Study of Two Different Dose Combinations of Nivolumab in Combination with Ipilimumab in Subjects with Previously Untreated, Unresectable or Metastatic MelanomaSubjects with Previously Untreated, Unresectable or Metastatic MelanomaMedDRA version: 19.0Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-004920-67-NLBristol-Myers Squibb International Corporation460
进行中（未招募）
1 期
A Randomized, Double Blinded, Study of Two Different Dose Combinations of Nivolumab in Combination with Ipilimumab in Subjects with Previously Untreated, Unresectable or Metastatic MelanomaSubjects with Previously Untreated, Unresectable or Metastatic MelanomaMedDRA version: 20.0Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-004920-67-DKBristol-Myers Squibb International Corporation460